Time to FOCUS on oral corticosteroid stewardship in asthma management

Claire McBrien, Andrew Menzies‐Gow

Respirology · 2019 · 12 citations · 7 references

DOIFull text

Open access

Concepts

Abstract

Asthma is the most prevalent long-term respiratory condition affecting approximately 339 million people worldwide, with around 1000 deaths each day attributed to it. Oral corticosteroid (OCS) therapy was first shown to be effective for acute asthma exacerbations in 1956.1 Since then, OCS treatment has been central to the management of exacerbations. Inhaled corticosteroids (ICS) were developed in the 1970s and have a key role in all national and international treatment algorithms, together with long-acting beta-agonists (LABA). In people who require high-dose ICS/LABA therapy ± other asthma modifiers to achieve control (i.e. those with severe asthma), maintenance OCS treatment is often initiated in order to gain further symptomatic relief and/or reduce the frequency of exacerbations. Over half of the patients on the British Thoracic Society Difficult Asthma Registry were prescribed maintenance OCS at the time of referral to a specialist centre.2 Unfortunately, OCS therapy is associated with numerous adverse effects. In the short term, patients may experience dyspepsia, insomnia or (rarely) psychosis. Longer term complications of frequent OCS courses or maintenance OCS therapy include weight gain, osteoporosis, type 2 diabetes, cataracts and increased risk of pneumonia and cardiovascular disease.3 It is difficult to quantify the true healthcare cost of maintenance OCS therapy. The pills themselves have a low price tag, but the ramifications of an increased rate of type 2 diabetes, to pick just one example, are wide-ranging and costly both at individual and population levels. The risk of OCS-induced adverse consequences begins at a cumulative dose of just 2–2.5 g.3 Similar concerns have previously been identified with antibiotics when the combination of over prescribing for viral infections and the increasing development of antimicrobial resistance led to the development of antimicrobial stewardship. The heterogeneity of asthma has been described in increasing depth, first with the identification of different phenotypes (clusters of characteristics shared by groups of people with asthma) and more recently with the detailed characterization of asthma endotypes (which may be thought of as sub-types of asthma dominated by specific biological processes). When considering how to reduce the burden of OCS treatment for a person with severe asthma, identification of their endotype is important as it informs the selection of the appropriate targeted therapy for that individual. It is also crucial to recognize situations in which OCS treatment is less effective, for example in cases of steroid-refractory asthma or of misdiagnosis (in which asthma is not the main cause of the patient's symptoms). In rheumatology, the development of effective disease-modifying and biologic therapies for rheumatoid arthritis has brought about a paradigm shift in treatment algorithms whereby OCS, previously viewed as the mainstay of treatment, have been relegated to use only as ‘bridging’ therapy to a disease-modifying drug. As advocates for patients with asthma, we are duty-bound to drive a comparable transformation in asthma care, with the aim of providing safe, effective treatments, targeted to the individual and backed up by a robust evidence base. Patients requiring frequent courses of OCS (and therefore exposed to potentially harmful cumulative doses of OCS) should be identified and referred promptly to a severe asthma service. A systematic assessment, under the care of a specialist multidisciplinary team, should include objective confirmation of the diagnosis, along with the identification and management of alternative/additional conditions. Doing the basics well can help minimize OCS exposure. Patient education, engagement and empowerment should be prioritized. Inhaler technique, adherence and modifiable risk factors (e.g. smoking) should be addressed. ICS/LABA treatment (drugs, dose and device) should be optimized and add-on therapies considered, such as a long-acting muscarinic antagonist (LAMA) inhaler and leukotriene antagonists. If appropriate, maintenance and reliever therapy (MART) or long-term macrolide treatment can be offered. If, even after optimization of all other facets of asthma care, maintenance OCS treatment or frequent OCS courses remain necessary, targeted therapies should be considered, guided by phenotype and key biomarkers such as the peripheral blood eosinophil counts, serum immunoglobulin E (IgE), sputum eosinophil count and/or fractional exhaled nitric oxide (FeNO) level. Biologic therapies, when delivered to selected patient groups, result in lower exacerbation rates. Steroid-sparing effects have been demonstrated for omalizumab,4 mepolizumab,5 benralizumab6 and dupilumab.7 Once asthma control is achieved, OCS weaning should commence as a priority. Careful OCS weaning should also be considered for patients who exhibit a type-2 low phenotype and who do not appear steroid-responsive. After several weeks/months of OCS therapy, adrenal insufficiency may develop and should be addressed in co-operation with endocrinology colleagues. Although OCS treatment has alleviated asthma symptoms for more than 60 years, the time has come to stop relying on this ‘double-edged sword’, which causes our patients numerous distressing and costly adverse effects. Systematic clinical assessment, in combination with increasingly sophisticated biomarkers, allows us to identify patients who are most likely to benefit from novel targeted therapies. A robust co-ordinated approach to OCS stewardship in asthma is required, in which burst and maintenance OCS exposure should be minimized. Significant further research and the development of additional novel therapies are required before we will confidently be able to claim that maintenance OCS therapy in severe asthma has been consigned to history. C.N.M. has attended an international conference with Boehringer Ingelheim and a national meeting with Teva. A.M.G. has attended advisory boards for GlaxoSmithKline, Novartis, AstraZeneca, Boehringer Ingelheim, Teva and Sanofi. He has received speaker fees from Novartis, AstraZeneca, Vectura, Boehringer Ingelheim and Teva. He has participated in research for which his host institution has been renumerated with Hoffman La Roche, GlaxoSmithKline, Boehringer Ingelheim and Astra-Zeneca. He has attended international conferences sponsored by Teva and Boehringer Ingelheim and has consultancy agreements with AstraZeneca, Vectura and Sanofi.

References

7